Pyzchiva is supplied as a 45mg/0.5mL and a 90mg/mL single-dose prefilled syringe for subcutaneous (SC) injection, and a 130mg/26mL single-dose vial for intravenous (IV) infusion. According to Sandoz, ...

Study participants were randomly assigned 1:1:1 to receive povorcitinib 45mg, povorcitinib 75mg, or placebo once daily. The primary endpoint was the proportion of participants who achieved ...

The US-based company’s Stop-HS1 (NCT05620823) and Stop-HS2 (NCT05620836) trials hit their primary endpoints with both doses of povorcitinib, 45mg and 75mg, with a higher proportion of patients treated ...